New Delhi, Sept. 24 -- The US Food and Drug Administration (FDA) has raised the risk classification of a recall involving Vitruvias Therapeutics' thyroid tablets after testing found that the medicine could be "superpotent", meaning it may contain more thyroid hormone than intended.

AS per the FDA, a Class I recall means that using the product could reasonably be expected to cause serious adverse health consequences or death.

The recall covers one specific lot of Vitruvias Therapeutics' Thyroid Tablets, USP 30 mg.

The affected product is identified by lot number 504950 and National Drug Code number 69680-166-00, with an expiration date of 30 September 2026. Of approximately 3,655 units distributed, roughly 1,955 were sold. The tablets w...